Prevymis (letermovir) - Merck (MSD)
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - Mar 24, 2026 - P=N/A | N=80 | Recruiting | Sponsor: Beijing Children's Hospital 
New trial • Bone Marrow Transplantation • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Rare Diseases • Transplantation
http://clinicaltrials.gov/ct2/show/NCT07488728
 
Mar 24, 2026
 
Prev Next